Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind placebo controlled multicenter study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS)

Next Previous
X
Search
Trial Profile

A double-blind placebo controlled multicenter study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dirucotide (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MAESTRO-01
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 09 Sep 2009 Data have been presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 27 Jul 2009 Primary endpoint time to disease progression as assessed using the Expanded Disability Status Scale (EDSS) has not been met, according to an Eli Lilly media release. On the basis of this result, the MAESTRO-02 trial has been discontinued.
    • 23 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top